Logo image of RNAC

CARTESIAN THERAPEUTICS INC (RNAC) Stock Fundamental Analysis

USA - NASDAQ:RNAC - US8162123025 - Common Stock

7.24 USD
-0.63 (-8.01%)
Last: 11/10/2025, 8:00:02 PM
7.52 USD
+0.28 (+3.87%)
After Hours: 11/10/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RNAC. RNAC was compared to 531 industry peers in the Biotechnology industry. While RNAC seems to be doing ok healthwise, there are quite some concerns on its profitability. RNAC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RNAC has reported negative net income.
RNAC had a negative operating cash flow in the past year.
RNAC had negative earnings in 4 of the past 5 years.
RNAC had negative operating cash flow in 4 of the past 5 years.
RNAC Yearly Net Income VS EBIT VS OCF VS FCFRNAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

RNAC's Return On Assets of -10.00% is amongst the best of the industry. RNAC outperforms 83.62% of its industry peers.
Industry RankSector Rank
ROA -10%
ROE N/A
ROIC N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAC Yearly ROA, ROE, ROICRNAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAC Yearly Profit, Operating, Gross MarginsRNAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNAC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNAC has more shares outstanding
There is no outstanding debt for RNAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAC Yearly Shares OutstandingRNAC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RNAC Yearly Total Debt VS Total AssetsRNAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

RNAC has an Altman-Z score of -2.40. This is a bad value and indicates that RNAC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RNAC (-2.40) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.4
ROIC/WACCN/A
WACC8.75%
RNAC Yearly LT Debt VS Equity VS FCFRNAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

RNAC has a Current Ratio of 13.33. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.33, RNAC belongs to the top of the industry, outperforming 88.70% of the companies in the same industry.
RNAC has a Quick Ratio of 13.33. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.33, RNAC belongs to the top of the industry, outperforming 88.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.33
Quick Ratio 13.33
RNAC Yearly Current Assets VS Current LiabilitesRNAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.70% over the past year.
The Revenue has grown by 49.64% in the past year. This is a very strong growth!
The Revenue has been growing by 42.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
Revenue 1Y (TTM)49.64%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%

3.2 Future

Based on estimates for the next years, RNAC will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.96% on average per year.
The Revenue is expected to grow by 17.81% on average over the next years. This is quite good.
EPS Next Y82.49%
EPS Next 2Y29.98%
EPS Next 3Y18.56%
EPS Next 5Y11.96%
Revenue Next Year-95.31%
Revenue Next 2Y-88.51%
Revenue Next 3Y-76.47%
Revenue Next 5Y17.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RNAC Yearly Revenue VS EstimatesRNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
RNAC Yearly EPS VS EstimatesRNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNAC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAC Price Earnings VS Forward Price EarningsRNAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAC Per share dataRNAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as RNAC's earnings are expected to grow with 18.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.98%
EPS Next 3Y18.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (11/10/2025, 8:00:02 PM)

After market: 7.52 +0.28 (+3.87%)

7.24

-0.63 (-8.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners25.44%
Inst Owner Change1.03%
Ins Owners39.77%
Ins Owner Change0.08%
Market Cap188.24M
Revenue(TTM)38.91M
Net Income(TTM)-38.89M
Analysts82.67
Price Target37.16 (413.26%)
Short Float %20.39%
Short Ratio29.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.03%
Min EPS beat(2)5.53%
Max EPS beat(2)160.52%
EPS beat(4)3
Avg EPS beat(4)43%
Min EPS beat(4)-21.74%
Max EPS beat(4)160.52%
EPS beat(8)4
Avg EPS beat(8)-105.15%
EPS beat(12)6
Avg EPS beat(12)-124.09%
EPS beat(16)9
Avg EPS beat(16)-60.97%
Revenue beat(2)1
Avg Revenue beat(2)-13.39%
Min Revenue beat(2)-64.04%
Max Revenue beat(2)37.26%
Revenue beat(4)1
Avg Revenue beat(4)-34.36%
Min Revenue beat(4)-83.4%
Max Revenue beat(4)37.26%
Revenue beat(8)4
Avg Revenue beat(8)179.53%
Revenue beat(12)5
Avg Revenue beat(12)112.77%
Revenue beat(16)9
Avg Revenue beat(16)115.64%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.73%
EPS NY rev (1m)0%
EPS NY rev (3m)38.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-70.03%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)-49.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS0.07
BVpS-0.1
TBVpS-7.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 420.1%
Cap/Sales 567.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.33
Quick Ratio 13.33
Altman-Z -2.4
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)302.59%
Cap/Depr(5y)221.09%
Cap/Sales(3y)8.41%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
EPS Next Y82.49%
EPS Next 2Y29.98%
EPS Next 3Y18.56%
EPS Next 5Y11.96%
Revenue 1Y (TTM)49.64%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%
Revenue Next Year-95.31%
Revenue Next 2Y-88.51%
Revenue Next 3Y-76.47%
Revenue Next 5Y17.81%
EBIT growth 1Y-66.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-65.62%
EBIT Next 5Y-21.06%
FCF growth 1Y-65.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.76%
OCF growth 3YN/A
OCF growth 5YN/A

CARTESIAN THERAPEUTICS INC / RNAC FAQ

What is the ChartMill fundamental rating of CARTESIAN THERAPEUTICS INC (RNAC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RNAC.


What is the valuation status for RNAC stock?

ChartMill assigns a valuation rating of 0 / 10 to CARTESIAN THERAPEUTICS INC (RNAC). This can be considered as Overvalued.


How profitable is CARTESIAN THERAPEUTICS INC (RNAC) stock?

CARTESIAN THERAPEUTICS INC (RNAC) has a profitability rating of 1 / 10.